The mechanism of action of Sandostatin® LAR®
Sandostatin® LAR® is a somatostatin analog. Its effects in the body are similar to those of the naturally occurring hormone, except that Sandostatin® LAR® remains active much longer than somatostatin.1
Sandostatin® LAR® works at the site of the tumor and binds with high affinity to subtype-2 (sst2) and with moderate affinity to subtype-5 (sst5).2 Binding with both of these broadly expressed somatostatin receptors helps to regulate gastrointestinal hormone secretion and affect tumor growth.3
30 mg of Sandostatin® LAR® more than doubled time to progression in first-line patients with advanced midgut NET (14.3 months vs 6.0 months with placebo [P=0.000072]).3
References:
1. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 1989:38:658-702. 2. Biller BMK, Colao A, Petersenn S, Bonert VS, Boscaro M. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord. 2010;10:1-14. 3. Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663. 4. Waser B, Cescato R, Liu Q, et al. Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients. Am J Pathol. 2012;180(5):1942-1949.